CARL CARLSMED, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1794546 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.4%
TTM net income YoY-55.6%
TTM EPS YoY65.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin77.0%
Operating margin-59.0%
Net margin-55.8%
FCF margin-48.6%
EBITDA margin-58.4%
Returns
ROE-43.9%
ROA-32.0%
ROIC (approx.)-108.1%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.20x
Current ratio5.79x
Interest coverage-33.33x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $50.51M | $27.16M |
| Cost of revenue | $12.47M | $7.12M |
| Gross profit | $38.04M | $20.05M |
| R&D expense | $17.02M | $14.30M |
| SG&A expense | $16.57M | $8.39M |
| Operating income | -$30.57M | -$24.12M |
| Interest expense | $1.43M | $1.32M |
| Income tax | $0 | $0 |
| Net income | -$29.63M | -$24.26M |
| EBITDA | -$30.29M | -$23.98M |
| EPS (basic) | -2.12 | -6.11 |
| EPS (diluted) | -2.12 | -6.11 |
| Weighted avg. shares (diluted) | 14.22M | 4.07M |
| Balance sheet | ||
| Cash & equivalents | $85.79M | $40.12M |
| Short-term investments | $24.00M | $0 |
| Receivables | $11.36M | $6.77M |
| Inventory | $1.84M | $995,000 |
| Current assets | $126.67M | $49.35M |
| PP&E, net | $1.49M | $260,000 |
| Total assets | $130.12M | $51.82M |
| Current liabilities | $14.28M | $8.82M |
| Long-term debt | $15.35M | $15.41M |
| Total debt | $15.35M | $15.41M |
| Total liabilities | $31.25M | $26.23M |
| Shareholders' equity | $98.87M | -$70.63M |
| Net debt | -$70.45M | -$24.71M |
| Shares outstanding | 26.60M | 4.14M |
| Cash flow statement | ||
| Operating cash flow | -$28.98M | -$25.47M |
| Capital expenditure | $642,000 | $180,000 |
| Free cash flow | -$29.62M | -$25.65M |
| Investing cash flow | -$25.48M | -$180,000 |
| Financing cash flow | $100.13M | $58.50M |
| Depreciation & amortization | $281,000 | $145,000 |
| Stock-based compensation | $1.93M | $253,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.